Koyfin Home > Directory > Health Care > Rigel Pharmaceuticals > EBITDA Margin

Rigel Pharmaceuticals EBITDA Margin Chart (RIGL)

Rigel Pharmaceuticals annual/quarterly EBITDA Margin from 2010 to 2020. An EBITDA margin is a measurement of a company's earnings before interest, taxes, depreciation, and amortization as a percentage of its total revenue.
  • Rigel Pharmaceuticals EBITDA Margin for the quarter ending June 06, 2020 was $-108m a 47.07% decrease of -51m year over year
  • Rigel Pharmaceuticals EBITDA Margin for the last 12 months ending June 06, 2020 was $-23m a -156.10% increase of 36m year over year
  • Rigel Pharmaceuticals Annual EBITDA Margin for 2019 was $-115m a -40.37% increase of 47m from 2018
  • Rigel Pharmaceuticals Annual EBITDA Margin for 2018 was $-162m a -989.86% increase of 1,603m from 2017
  • Rigel Pharmaceuticals Annual EBITDA Margin for 2017 was $-1,765m a 82.48% decrease of -1,456m from 2016
Other Margins & Efficiency Metrics:
  • Rigel Pharmaceuticals Return on Capital % for the quarter ending September 09, 2018 was -53.67 a -55.75% increase of 29.92 year over year
  • Rigel Pharmaceuticals Return on Equity % for the quarter ending September 09, 2018 was -83.74 a -57.61% increase of 48.24 year over year
View Chart On Koyfin

Quarterly RIGL EBITDA Margin Data

06/2020$-108m
03/2020$38m
12/2019$-111m
09/2019$-57m
06/2019$-203m
03/2019$-144m
12/2018$7m
09/2018$-498m
06/2018$-1,452m
09/2017$-1,971m

Annual RIGL EBITDA Margin Data

2019$-115m
2018$-162m
2017$-1,765m
2016$-309m
2015$-174m
2014$-1,077m
2013$-1,192m
2012$-4,309m
2011$-1,777m
2010$29m